Treatment of rheumatic diseases and hepatitis B virus coinfection

Rheumatology International

Volumn 35, Issue 3, 2015, Pages 385-392

  Felis Giemza, Anna ^a   Olesińska, Marzena ^a   Świerkocka, Katarzyna ^a   Więsik Szewczyk, Ewa ^a   Haładyj, Ewa ^a  

^a INSTITUTE OF RHEUMATOLOGY   (Poland)

Author keywords

Abatacept; Biological therapy; Hepatitis B; Rheumatic diseases; Rituximab; Tocilizumab

Indexed keywords

ABATACEPT; AZATHIOPRINE; CHLOROQUINE; ENTECAVIR; ETANERCEPT; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; RITUXIMAB; SALAZOSULFAPYRIDINE; TENOFOVIR; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VIRUS DNA; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; HEPATITIS B(E) ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

HEPATITIS B; HEPATITIS B VIRUS; HETEROZYGOTE; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION PREVENTION; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SEROCONVERSION; VIRUS LOAD; VIRUS REACTIVATION; COMPLICATION; HEPATITIS B, CHRONIC; IMMUNOLOGY; RHEUMATIC DISEASES;

ABATACEPT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RHEUMATIC DISEASES; RITUXIMAB;

EID: 84923834385     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-014-3195-8     Document Type: Review

References (87)

1. Juszczyk J (2000) Clinical course and consequences of hepatitis B infection. Vaccine 18:S23–S25
2. Tiollais P, Charnay P, Vyas GN (1981) Biology of hepatitis B virus. Science 213:406–411
3. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF (2001) Nomenclature for antiviral resistant of human hepatitis B virus mutations in the polymerase region. Hepatology 33:751–757
4. Ferir G, Kaptein S, Neyts J, De Clercq E (2008) Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future. Rev Med Virol 18:19–34
5. Morgan M, Keeffe EB (2009) Diagnosis and treatment of chronic hepatitis B: 2009 update. Minerva Gastroenterol Dietol 55:5–22
6. Pungpapong S, Kim WR, Poterucha JJ (2007) Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc 82:967–975
7. Winthrop KL, Calabrese LH (2011) Let the fog be lifted: screening for hepatitis B virus before biological therapy. Ann Rheum Dis 70:1701–1703
8. Szczeklik A (2010) Choroby wewnętrzne. Medycyna Prakt, pp 967–980
9. Chisari FV, Isogawa M, Wieland S (2010) Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 58(4):258–266
10. Hösel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ, Langenkamp A, Falk C, Büning H, Rose-John S, Protzer U (2009) Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology 50(6):1773–1782
11. Puro R, Schneider RJ (2007) Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA. J Virol 81(14):7351–7362
12. Yapali S, Talaat N, Lok AS (2014) Management of hepatitis B: our practice and how it relates to the guidelines. Clin Gastroenterol Hepatol 12(1):16–26
13. de Franchis R, Hadengue A, Lau G et al (2003) EASL Jury. EASL International consensus conference on hepatitis B. Consensus statement (long version). J Hepatol 39(Suppl. 1):S3–S25
14. Tang JR, Hsu HY, Lin HH et al (1998) Hepatitis B surface antigenemia at birth: a long-term followup study. J Pediatr 133:374–377. www.who.int
15. Yeo W, Chan PKS, Zhong S, Ho WM, Steinberg JL, Tam JS, Hui P, Leung NWY, Zee B, Johnson PJ (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299–307
16. Yeo W, Johnson PJ (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43(2):209–220
17. Brojer E (2009) Ukryte zakażenie wirusem HBV w hematologii i transfuzjologii. Acta Haematol Pol 40(2):435–449
18. Vassilopoulos D (2011) Should we routinely treat patients with autoimmune/rheumatic diseases and chronic hepatitis B virus infection starting biologic therapies with antiviral agents? Yes. Eur J Int Med 22:572–575
19. Perrillo RP (2001) Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120:1009–1022
20. Evens AM, Jovanovic BD, Su YC et al (2011) Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 22:1170–1180
21. Mendez-Navarro J, Corey KE, Zheng H et al (2011) Hepatitis B screening, prophylaxis and reactivation in the era of rituximab-based chemotherapy. Liver Int 31:330–339
22. Chen XQ, Peng JW, Lin GN et al (2012) The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg—positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy. Med Oncol 29:1237–1241
23. Pyrpasopoulou A, Douma S, Vassiliadis T et al (2011) Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 31:403–404
24. Mitroulis I, Hatzara C, Kandili A et al (2013) Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 72:308–310
25. Tsutsumi Y, Shigematsu A, Hashino S et al (2009) Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin’s lymphoma in Hokkaido. Ann Hematol 88(4):375–377
26. Yang SH, Kuo SH (2008) Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol 87(4):325–327
27. Yeo W, Chan TC, Leung NWY et al (2009) Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27(4):605–611
28. Nagashima T, Minota S (2008) Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology (Oxford) 47:1838–1840
29. Nagashima T, Maruyama A, Kamata Y et al (2011) Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection. Rheumatol Int 32:2231–2232
30. Tsuboi H, Tsujii A, Nampei A et al (2011) A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B. Mod Rheumatol 21:701–705
31. Kim PS, Ho GY, Prete PE et al (2012) Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B. Arthritis Care Res (Hoboken) 64:1265–1268
32. Ghrenassia E, Meknian A, Rouaghe S, Granne N, Fain O (2012) Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine 79:100–101
33. Salman-Monte TC, Lisbona MP, García-Retortillo M, Maymóa J (2014) Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab. Reumatol Clin 10(3):191–200
34. Germanidis G, Hytiroglou P, Zakalka M, Settas L (2012) Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol 56(6):1420–1421
35. Vassilopoulos D, Calabrese LH (2012) Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol 8(6):348–357
36. Jong EC, Freedman DO (2009) The immunocompromised traveler. In:CDC travelers’ health yellow book. http://wwwn.cdc.gov/travel/yellowbook/2010/chapter-8/immunocompromisedtraveler.aspx
37. Stuck AE, Minder CE, Frey FJ (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11:954–963
38. Xuan D, Yiqi Y, Shao L, Wang J, Zhang W, Zou H (2014) Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy—a report of long-term follow-up of serial cases and literature review. Clin Rheumatol 33:577–586
39. Bae JH, Sohn JH, Lee HS, Park HS, Hyun YS, Kim TY, Eun CS, Jeon YC, Han DS (2012) A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier. Clin Mol Hepatol 18(2):225–228
40. Cheng J, Li JB, Sun QL, Li X (2011) Reactivation of hepatitis B virus after steroid treatment in rheumatic diseases. J Rheumatol 38(1):181–182. doi:10.3899/jrheum.100692
41. Watanabe K, Takase K, Ohno S, Ideguchi H, Nozaki A, Ishigatsubo Y (2012) Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate. Mod Rheumatol 22(3):470–473
42. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, Motomura S (2011) Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol 21(1):16–23
43. Tan J, Zhou J, Zhao P, Wei J (2012) Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs. Clin Rheumatol 31(8):1169–1175
44. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, Enomoto M, Inaba M, Nakatani T, Hino M, Kawada N (2011) Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol 46(4):556–564
45. Ito S, Nakazono K, Murasawa A, Mita Y, Hata K, Saito N, Kikuchi M, Yoshida K, Nakano M, Gejyo F (2001) Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 44(2):339–342
46. Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S (2014) Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease modifying antirheumatic drugs. Int J Rheum Dis. doi:10.1111/1756-185X.12359
47. Lee YM, Kang M, Hwang JM, Lee S, Cho H, Kim YS (2010) Sulfasalazine induces apoptosis of HBxexpressing cells in an NF-kappaB-independent manner. Virus Genes 40(1):37–43
48. Thong BY, Koh ET, Chng HH, Chow WC (2007) Outcomes of chronic hepatitis B infection in oriental patients with rheumatic diseases. Ann Acad Med Singap 36(2):100–105
49. Narváez J, Rodriguez-Moreno J, Martinez-Aguilá MD, Clavaguera MT (1998) Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol 25(10):2037–2038
50. Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N (2004) Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of lowdose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 22(3):375–376
51. Mok MY, Ng WL, Yuen MF, Wong RW, Lau CS (2000) Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. Clin Exp Rheumatol 18(3):363–368
52. Helbling B, Reichen J (1994) Reactivation of hepatitis B following withdrawal of chloroquine. Schweiz Med Wochenschr 124(18):759–762
53. Tonziello G, Pisaturo M, Sica A, Ferrara MG, Sagnelli C, Pasquale G, Sagnelli E, Guastafierro S, Coppola N (2013) Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection 41:225–229
54. Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, Hernandez-Navarro F (2008) Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment? Am J Hematol 83:673–675
55. Sagnelli E, Pisaturo M, Martini S, Filippini P, Sagnelli C, Coppola N (2014) Clinical impact of occult hepatitis B virus infection in immunosuppressed patients. World J Hepatol 6(6):384–393
56. Viganò M, Mangia G, Lampertico P (2014) Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy. Expert Opin Biol Ther 14(7):1019–1031
57. Penn H (2006) Biologic therapies in autoimmune diseases. Clin Med 6:105
58. Weaver AL (2003) Differentiating the new rheumatoid arthritis biologic therapies. J Clin Rheumatol 9:99–114
59. Peterson JR, Hsu FC, Simkin PA et al (2003) Effect of tumor necrosis factor α antagonism on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 62:1078–1082
60. Su F, Schneider RJ (1997) Hepatitis B virus Hbx protein sensitizes cells to apoptotic killing by tumor necrosis factor α. Proc Natl Acad Sci USA 94:8744–8749
61. Maini MK, Boni C, Lee CK (2000) The role of virus specific CD8 + cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med 191:1269–1280
62. Millonig G, Kern M, Ludwiczek O et al (2006) Subfulminant hepatitis B after infliximab in Crohn’ disease: need for HBV-screening? World J Gastroenterol 12:974–976
63. Uhl EW, Moldawer LL, Busse WW et al (1998) Increased tumor necrosis factor α (TNF-α) gene expression in parainfluenza type 1 (Sendai) virus-inducted bronchiolar fibrosis. Am J Pathol 152:513–522
64. Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh ChW, Chen DY, Yang SS (2011) Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 70:1719–1725
65. Loomba R, Rowley A, Wesley R et al (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519–528
66. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F et al (2011) Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore) 90(6):359–371
67. Giles JT, Bathon JM (2004) Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 19:320–334
68. Keane J, Gershon S, Wise SP et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 345:1098–1103
69. Carrol BM, Bond IM (2008) Use of tumor necrosis factor-α inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 38:208–217
70. Thimme R, Wieland S, Steiger C et al (2003) CD8 + cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 77:68–76
71. Sakellaoriu GT, Chatzigiannis I (2007) Long term anti-TNF-alpha therapy for ankylosis spondylitis in two patients with chronic HBV infection. Clin Rheumatol 26:950–952
72. Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusion of anti-tumor necrosis factor hepatitis α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552–1563
73. Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F (2008) Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases. Autoimmun Rev8:104–106
74. Furst DE, Keystone EC, Braun J et al (2011) Updated consensus statement on biological agents for the treatment of rheumatic diseases 2010. Ann Rheum Dis 70(Suppl 1):i2–i36
75. Nathan DM, Angus PW, Gibson PR (2006) Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 21:1366–1371
76. Wendling D, Di Martino V, Prati C et al (2009) Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine 76:308–311
77. Marzano A, Angelucci E, Andreone P et al (2007) Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 39:397–408
78. Galeazzi M, Bellisai F, Giannitti C et al (2007) Safety of cyclosporin A in HCV-infected patients: experience with cyclosporin A in patients affected by rheumatological disorders and concomitant HCV infection. Ann NY Acad Sci 1110:544–549
79. Giannitti C, Benucci M, Caporali R et al (2009) Efficacy and safety of anti-TNF-alpha therapy combined with cyclosporine A in patients with rheumatoid arthritis and concomitant hepatitis C virus infection. Int J Immunopathol Pharmacol 22:543–546
80. Esteve i Comas M, Saro C, Gonzales-Huix F et al (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut 53:1363–1365
81. Michel M, Duvoux C, Hezode C et al (2003) Fulminant hepatitis after infliximab in patient with hepatitis B virus treated for an adult onset Still’s disease. J Rheumatol 30:1624–1625
82. Caporali R, Bobbio-Pallavicini F, Atzeni F et al (2010) Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases. Arthritis Care Res 62:749–754
83. Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S (2003) Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 62:686–687
84. Chung SJ, Kim JK, Park MC, Park YB, Lee SK (2009) Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 36:2416–2420
85. Kim YJ, Bae SC, Sung YK et al (2010) Possible reactivation of potential hepatitis B virus occult infection by tumor necrosis factor-alpha blocker in the treatment of rheumatic diseases. J Rheumatol 37:346–350
86. Singh JA, Furst DE, Bharat A et al (2012) 2012 Update of the 2008 American College of rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 64:625–639
87. Zingarelli S, Frassi M, Bazzani C et al (2009) Use of tumor necrosis factor-α-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 36:1189–1194